Evidence map›Paper›PMID 42508408›Full record

ArticleCancer cell2026

Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.

R Ryan Meyerhoff, Alan Chen, Jenny O'Brien, Carmen M Anadon, Luis Uriel Lopez Bailon, Dayan Carrion-Estrada, Koravit Poysungnoen, Jared Lindenberger, Gabor Kemeny, Liliana Lyniv and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

R Ryan MeyerhoffDivision of Interventional Radiology, Department of Radiology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: meyerhr@mskcc.org.
Alan ChenDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Jenny O'BrienDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Carmen M AnadonDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC 27710, USA.
Luis Uriel Lopez BailonDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Dayan Carrion-EstradaDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Koravit PoysungnoenDepartment of Biomedical Engineering, Duke University, Durham, NC 27710, USA.
Jared LindenbergerDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Gabor KemenyDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Liliana LynivDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Vaibjav JainDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Ricardo ChaurioDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC 27710, USA.
Noah PlappertDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC 27710, USA.
Tyler EvangelousDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Chan Soo ParkDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Alok SinhaDepartment of Chemistry, Duke University, Durham, NC 27710, USA; Department of Computer Science, Duke University, Durham, NC 27710, USA.
Eziafa OduahDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Carolyn GlassDepartment of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
Kent WeinholdDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
Simon GregoryDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC 27710, USA.
John W HickeyDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Priyamvada AcharyaDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Neal ReadyDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Jose R Conejo-GarciaDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC 27710, USA.
Wilton B WilliamsDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: wilton.williams@duke.edu.
Scott J AntoniaDivision of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: scott.antonia@duke.edu.

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
Vascular Leukocytes Influence the Tumor MicroenvironmentR01CA124515 · NCI · WISTAR INSTITUTE · PI Jose R Conejo-Garcia · 2007 to 2026
$7.1M
Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapiesR01CA278907 · NCI · DUKE UNIVERSITY · PI Jose R Conejo-Garcia · 2023 to 2026
$1.5M
Duke Radiation Oncology and Radiology Stimulating Access to Research in ResidencyR38CA245204 · NCI · DUKE UNIVERSITY · PI FLOYD, SCOTT R · 2020 to 2023
$1.4M
Novel immunotherapies using optimized tumor cell-penetrating antibodiesR01CA297896 · NCI · DUKE UNIVERSITY · PI Jose R Conejo-Garcia · 2025 to 2026
$1.2M
Leica Stellaris Confocal for a Campus-wide Shared ResourceS10OD034340 · OD · DUKE UNIVERSITY · PI CAMERON, LISA A. · 2024 to 2024
$686k
OR2H1 is an effective target for CAR T cells in human epithelial tumorsR21CA276205 · NCI · DUKE UNIVERSITY · PI CONEJO-GARCIA, JOSE R · 2023 to 2024
$409k
NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA124515NCI NIH HHS R01 CA278907NCI NIH HHS R01 CA297896NCI NIH HHS R21 CA276205NCI NIH HHS R38 CA245204NIH HHS S10 OD034340
6 · The paper itself

Abstract

The role of tumor-infiltrating B cells (TIL-Bs) in shaping anti-tumor responses in the context of immune checkpoint blockade remains incompletely understood. Here, we interrogate the humoral response in resected lung tumors from patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant PD-1 blockade. We find that tumors orchestrate tertiary lymphoid structures with CD138

Indexed as

Antibodies, MonoclonalCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsLymphocytes, Tumor-InfiltratingPlasma CellsProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorHumansMiceAntibodies, MonoclonalImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorchimeric antigen receptor T cellscitrullinated vimentinplasma cells in NSCLCtumor antibodiestumor antigenstumor-infiltrating B cellstumor-reactive antibodiestumor-reactive B cellstumor-suppressive myeloid cells

Identifiers

PMID42508408
PMCPMC13526486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.